Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.00
Low: 0.00
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Miners lift FTSE 100 as Fed meeting kicks off

Tue, 25th Jul 2023 12:08

(Alliance News) - Stock prices in London were largely higher at midday on Tuesday, with stimulus talks in China helping lift the mood, as attention turns to the US Federal Reserve which begins its two-day monetary policy meeting later.

The FTSE 100 index was up 9.63 points, or 0.1%, at 7,688.22. The FTSE 250 was down 24.77 points, or 0.1%, at 19,120.21, and the AIM All-Share was up 2.18 points, or 0.3%, at 765.78.

The Cboe UK 100 was flat at 766.86, the Cboe UK 250 was flat at 16,796.11, and the Cboe Small Companies was flat at 13,429.44.

Chinese leaders on Monday pledged fresh measures to boost the nation's stuttering economy, building on optimism that central banks were nearing the end of their rate-hiking cycle.

After a meeting, the 24-person Politburo recognised "the current economic operation is facing new difficulties and challenges" and agreed they must "implement precise and effective macroeconomic regulation, strengthen countercyclical regulation and policy reserves".

Danni Hewson, head of financial analysis at AJ Bell, said that while detail remains "thin on the ground" at present, it was enough to lift the Hang Seng by 4.1% and send commodity stocks in the UK higher.

At midday in London, Anglo American was up 4.2%, Antofagasta up 4.3%, Rio Tinto up 3.6%, and Glencore up 1.7%. Asia-focused insurer Prudential also rose 3.5%.

Unilever was the best-performing blue-chip stock at midday, rising 4.6% after reporting double-digit interim profit growth, while volumes were steady from the prior year.

The consumer goods firm reported that pretax profit jumped 21% to GBP5.27 billion in the first half of 2023, from GBP4.36 billion a year before. Revenue rose 2.7% year-on-year to GBP30.43 billion, compared to GBP29.62 billion.

"Things should get easier from here as costs are expected to ease over the second half. That'll give room to take the foot off the pedal when it comes to price hikes - good news for consumers, and it should release some pressure on volumes," said Matt Britzman, equity analyst at Hargreaves Lansdown.

Compass Group was the FTSE 100's worst-performer, meanwhile, down 4.6%, despite posting strong organic growth in its financial third quarter and leaving its full-year guidance unchanged.

The contract caterer said organic revenue growth was 15% in the three months to June 30 and 21% in the year-to-date.

Consequently, Compass reiterated its annual guidance, expecting operating profit growth of 30% on a constant-currency basis, which is to be delivered through organic revenue growth of around 18% and an underlying operating margin in the range of 6.7% to 6.8%.

In the FTSE 250, Tyman added 6.1% after it said full-year adjusted operating profit would be at the top end of market expectations, despite reporting a drop in half-year pretax profit.

The supplier of engineered fenestration components and access solutions to the construction industry said pretax profit in the first half of 2023 had fallen to GBP22.7 million from GBP37.4 million the year prior. Revenue dropped to GBP329.9 million, from GBP360.0 million.

Interim Chief Executive Officer Jason Ashton said it was a "solid overall performance" against a strong comparative period and despite a continuation of the weak markets experienced in the fourth quarter of 2022.

Tyman said it expects full-year adjusted operating profit at the top end of market expectations, citing company-compiled analyst consensus of GBP80.8 million, within a GBP77.6 million to GBP84.3 million range. This would still mark a decrease from GBP94.6 million in 2022, however.

Elsewhere in London, Reach surged 19% after it said it expects 2023 profit to be in line with market consensus, despite a decline in revenue in the first half of the year.

Pretax profit in the 26 weeks that ended June 25 was GBP6.7 million, down more than two thirds from GBP32.0 million a year before, as revenue slipped 6.1% to GBP279.4 million from GBP297.4 million.

Reach said plans to reduce full-year operating costs by 5% to 6% are on track to deliver second-half weighted savings.

As a result, Reach said, profit expectations for 2023 remain in line with market consensus for adjusted operating profit of GBP94.9 million. This would be down 11% from adjusted operating profit of GBP106.1 million in 2022, however.

On AIM, N4 Pharma surged 27% as it celebrated a patent grant for Nuvec in the US.

N4 is a pharmaceutical company focused on the development of a novel silica nanoparticle delivery system, known as Nuvec, for vaccines and therapeutics for licensing to pharmaceutical and biotech partners.

The patent is for the composition of matter of the nanoparticle itself. It sits alongside the first US patent grant announced last January, which concerned how the nanoparticle is made using a broad description of the manufacturing process used by the company.

In European equities on Tuesday, the CAC 40 in Paris was up 0.2%, while the DAX 40 in Frankfurt was up 0.1%.

Stocks in New York were called largely flat as nerves built ahead of the US Federal Reserve's next interest rate decision. The Dow Jones Industrial Average was called marginally lower, the S&P 500 index was seen marginally higher, and the Nasdaq Composite was called up 0.2%.

The Fed starts its two-day policy meeting in just a couple of hours and is widely expected to announce a 25 basis point hike to interest rates on Wednesday.

However, with a rate hike on Wednesday all but guaranteed, markets will be focused on Fed Chair Jerome Powell's press conference shortly after the announcement, hoping for hints on when the current tightening cycles may end.

The dollar was mixed at midday as nerves built ahead of a busy week of consecutive interest rate decisions from the Fed, European Central Bank and the Bank of Japan from Wednesday.

The pound was quoted at USD1.2843 at midday on Tuesday in London, up from USD1.2816 at the close on Monday. The euro stood at USD1.1045, lower against USD1.1073. Against the yen, the dollar was trading at JPY141.43, higher compared to JPY141.27.

Brent oil was quoted at USD82.54 a barrel at midday in London on Tuesday, up from USD82.23 late Monday. Gold was quoted at USD1,960.61 an ounce, higher against USD1,958.30.

Still to come on Tuesday's economic calendar, there is a US consumer confidence reading at 1500 BST.

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 16:55

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.